D
Dmytro Butov
Researcher at Kharkiv National Medical University
Publications - 37
Citations - 222
Dmytro Butov is an academic researcher from Kharkiv National Medical University. The author has contributed to research in topics: Tuberculosis & Medicine. The author has an hindex of 7, co-authored 27 publications receiving 148 citations.
Papers
More filters
Journal ArticleDOI
Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo
Svetlana I Zaitzeva,S. L. Matveeva,T. G. Gerasimova,Y. N. Pashkov,Dmytro Butov,V. S. Pylypchuk,Valery M. Frolov,Galyna A Kutsyna +7 more
TL;DR: The anti-inflammatory property of Dzherelo was further supported by a favourable haematology profile, reduced erythrocyte sedimentation rate and faster defervescence, and is thus useful as an immunotherapeutic adjunct in the management of TB.
Journal ArticleDOI
Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7).
Yuri V Efremenko,Dmytro Butov,Natalia D Prihoda,Svetlana I Zaitzeva,Larisa V. Yurchenko,Nina I. Sokolenko,Tetyana Butova,Anna L Stepanenko,Galyna A Kutsyna,Vichai Jirathitikal,Aldar S. Bourinbaiar +10 more
TL;DR: A larger population of patients with prolonged follow-up is required to support the safety and efficacy of an orally-administered therapeutic TB vaccine (V7), as preliminary findings were below significance threshold.
Journal ArticleDOI
Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month
Aldar S. Bourinbaiar,Uyanga Batbold,Yuri V Efremenko,Munkhburam Sanjagdorj,Dmytro Butov,Narantsetseg Damdinpurev,Elena A. Grinishina,Otgonbayar Mijiddorj,Mikola E Kovolev,Khaliunaa Baasanjav,Tetyana Butova,Natalia D Prihoda,Ochirbat Batbold,Larisa V. Yurchenko,Ariungerel Tseveendorj,Olga Arzhanova,Erkhemtsetseg Chunt,Hanna Stepanenko,Nina I. Sokolenko,Natalia I. Makeeva,Marina G Tarakanovskaya,Vika Borisova,Alan A. Reid,Valeryi Kalashnikov,Peter Nyasulu,Satria A. Prabowo,Vichai Jirathitikal,Allen I Bain,Cynthia Ann Stanford,John Lawson Stanford +29 more
TL;DR: Oral M. vaccae is safe, can overcome TB-associated weight loss and inflammation, reduce hepatotoxicity of TB drugs, improve sputum conversion three-fold, and cut treatment length by at least six-fold.
Journal ArticleDOI
Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7).
Dmytro Butov,Yuri V Efremenko,Natalia D Prihoda,Svetlana I Zaitzeva,Larisa V. Yurchenko,Nina I. Sokolenko,Tetyana Butova,Anna L Stepanenko,Galyna A Kutsyna,Jirathitikal,Aldar S. Bourinbaiar +10 more
TL;DR: Oral M. vaccae was safe and has potential as an adjunct immunotherapy, targeting mucosal immunity, to improve efficacy and shorten treatment duration of TB chemotherapy.
Journal ArticleDOI
Adjunct immune therapy of first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV
Dmytro Butov,Yuri V Efremenko,Natalia D Prihoda,Larisa I Yurchenko,Nina I. Sokolenko,Olga V. Arjanova,Anna L Stepanenko,Tatiana Butova,Svetlana S Zaitzeva,Vichai Jirathitikal,Aldar S. Bourinbaiar,Galyna A Kutsyna +11 more
TL;DR: V5 is safe and effective as an immune adjunct to chemotherapy for TB and can potentially reduce the treatment duration down to 1 month, and no adverse side effects or reactivation of TB were seen at any time.